Arctic Bioscience – Revenue growth and HRO350 Phase IIb clinical trial on track
Highlights H1 2022 results:· HRO350 development on track with further projects in pipeline · First patient expected to be enrolled in Q4 2022 · Total revenue increased 20 % y/y to NOK 14,4 million in H1 2022, from NOK 12 million in H1 2021 · EBITDA of NOK -14,4 million in H1 2022 (NOK -19,9 million), with a gross margin of 27,6 % (26,0 %) · Solid financial position with NOK 177,8 million in cash by 30 June · Positive revenue prospects for H2 2022, including increased order intake from the Chinese market · Strong Management team in place, including new CEO, new CFO and new